Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Polyarthritis

Polyarthritis

Polyarthritis is a condition characterized by inflammation and swelling in multiple joints.
It can be caused by a variety of underlying conditions, such as rheumatoid arthritis, psoriatic arthritis, or reactive arthritis.
Symptoms may include joint pain, stiffness, and reduced range of motion.
Accurate diagnosis and effective treatment are crucial for managing polyarthritis and preventing long-term complications.
Reserach protocols that optimize the identifcation and evaluation of polyarthritis are essential for advancing our understanding and improving patient outcomes.

Most cited protocols related to «Polyarthritis»

1
Cardiovascular Risk Factor Protocol
Age at study entry (baseline)
Ethnic origin (nine categories)
Deprivation (as measured by the Townsend score, where higher values indicate higher levels of material deprivation)
Systolic blood pressure
Body mass index
Total cholesterol: high density lipoprotein cholesterol ratio
Smoking status (non-smoker, former smoker, light smoker (1-9/day), moderate smoker (10-19/day), or heavy smoker (≥20/day))
Family history of coronary heart disease in a first degree relative aged less than 60 years
Diabetes (type 1, type 2, or no diabetes)
Treated hypertension (diagnosis of hypertension and treatment with at least one antihypertensive drug)
Rheumatoid arthritis (diagnosis of rheumatoid arthritis, Felty’s syndrome, Caplan’s syndrome, adult onset Still’s disease, or inflammatory polyarthropathy not otherwise specified)
Atrial fibrillation (including atrial fibrillation, atrial flutter, and paroxysmal atrial fibrillation)
Chronic kidney disease (stage 4 or 5) and major chronic renal disease (including nephrotic syndrome, chronic glomerulonephritis, chronic pyelonephritis, renal dialysis, and renal transplant)
Hippisley-Cox J., Coupland C, & Brindle P. (2017). Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. The BMJ, 357, j2099.
Full text: Click here
Publication 2017
Adult-Onset Still Disease Antihypertensive Agents Atrial Fibrillation Atrial Flutter BLOOD Caplan Syndrome Cholesterol Chronic Kidney Diseases Diabetes Mellitus Diagnosis Ethnicity Felty Syndrome Fibrillation, Paroxysmal Atrial Glomerulonephritis Heart Disease, Coronary Hemodialysis High Blood Pressures High Density Lipoprotein Cholesterol Kidney Transplantation Light Nephrotic Syndrome Non-Smokers Polyarthritis Pyelonephritis Rheumatoid Arthritis Systole
2
Systematic Review of Outcome Measures in Psoriatic Arthritis

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2016
Arthritis Arthritis, Psoriatic Child Collagen Diseases Polyarthritis
3
Characterizing Anti-Jo-1 Autoantibody Syndrome
Twenty-four rheumatology centers from Italy, Spain, Germany, and the USA were involved in the study. We included patients with at least 2 anti Jo-1 positive tests, with 1 or more findings between arthritis, myositis, and ILD, and that signed the informed consent as approved by the local Institutional Ethics Board. Type and characteristics of clinical features, outcomes, laboratory and instrumental investigations, at the onset and during follow-up, were retrospectively collected.
As previously described,7 (link) ILD was defined instrumentally by a restrictive pulmonary function test pattern (Forced Vital Capacity (FVC) ≤ 80%, Forced Expiratory Volume in the first second (FEV1)/FVC ≥ 70%, decreased or normal FEV1, and/or <20% reduction in diffusing capacity of the lung for carbon monoxide), after excluding other causes different from ILD, and/or by signs of alveolitis/fibrosis on high-resolution computed tomography (HRCT).7 (link) ILD presentation was defined as acute/subacute when dyspnoea began acutely and progressed rapidly (within 4–6 weeks from symptom onset), chronic when dyspnoea began insidiously and progressed slowly, and asymptomatic when lung involvement was only instrumental. Screening for ILD occurrence was regularly performed during follow-up.
Patients with muscle enzyme elevation (creatinine phosphokinase and/or aldolase) and the presence of typical electromyography alterations and/or compatible muscle biopsy findings were considered as having muscle involvement. Myositis onset was defined as classic (muscle strength deficit) or hypomyopathic (instrumental/laboratory evidence of muscle impairment without strength deficit). Muscle enzymes were regularly assessed during follow-up.
Arthritis occurrence (joints swelling and tenderness required) and its presentation pattern (eg, symmetrical polyarthritis, oligoarticular/asymmetrical arthritis), fever, mechanic's hands, and Raynaud's phenomenon were assessed clinically. Plain X-rays were performed to identify joint erosions.
The onset of ASSD was considered from the first pulmonary, muscular or joint symptom. Clinical features onset was considered concurrent in cases of <3 months of delay between manifestations’ presentation. For practical purposes, patients with arthritis, ILD, and myositis were defined as having a complete ASSD, whereas patients lacking at least one of these features were defined as having an incomplete form.
Cavagna L., Nuño L., Scirè C.A., Govoni M., Longo F.J., Franceschini F., Neri R., Castañeda S., Giraldo W.A., Caporali R., Iannone F., Fusaro E., Paolazzi G., Pellerito R., Schwarting A., Saketkoo L.A., Ortego-Centeno N., Quartuccio L., Bartoloni E., Specker C., Murcia T.P., La Corte R., Furini F., Foschi V., Corral J.B., Airò P., Cavazzana I., Martínez-Barrio J., Hinojosa M., Giannini M., Barsotti S., Menke J., Triantafyllias K., Vitetta R., Russo A., Bajocchi G., Bravi E., Barausse G., Bortolotti R., Selmi C., Parisi S., Montecucco C, & González-Gay M.A. (2015). Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study. Medicine, 94(32), e1144.
Publication 2015
Arthritis Biopsy Creatinine Dyspnea Electromyography Enzymes Fever Fibrosis Forced Vital Capacity Fructosediphosphate Aldolase Joints Lung Monoxide, Carbon Muscle Strength Muscle Tissue Myositis Oligoarthritis Patients Phosphotransferases Polyarthritis Raynaud Phenomenon Tests, Pulmonary Function Volumes, Forced Expiratory X-Ray Computed Tomography X-Rays, Diagnostic
4
Evaluating Hip Arthroplasty Outcomes: Modified Merle d'Aubigné and Postel Method
The organizers contacted 96 patients monitored by the Hip Group of Santa Casa de
Misericórdia de São Paulo. Forty-five patients of both sexes, residing in
Greater São Paulo, and submitted to uni- or bilateral Total Hip Arthroplasty (THA),
were included in the study. The patients submitted to bilateral THA had only the side with
longer follow-up time evaluated. Patients with less than 6 months of THA postoperative (PO)
time were excluded. Of the 96 patients, 46 were not willing to take part in the study, and
five had less than six months of PO time.
All the patients received explanations regarding the goals and procedures of this survey
and in agreeing to take part in the study signed a consent form. The project of this study
was approved by the Institutional Review Board under no. 495/07.
The patients were evaluated by the Modified Merle d'Aubigné and Postel
Method9 (link) (Appendix 1), which evaluates pain, gait and mobility, on a scale of 1
to 6 for each item, where 1 indicates the worst and 6, the best state of the patient. The
total minimum score reached is 3, and the maximum is 18. In this modified method, the
patients are categorized by the alphabetical prefixes: Prefix A: patient with one hip
involved; B: patient with two hips involved; C: patient with systemic disease that
interferes in normal gait (polyarthritis in rheumatoid arthritis, senility, hemiplegia,
cardiovascular and pulmonary dysfunction), which are classified according to the clinical
and radiographic diagnosis.
The study used parameters to standardize the gait options. Option 6: indicated patient with
normal gait; 5: limping gait without use of crutches; 4: patient who walks long distances
with cane (parameterized as the individual who walks in the park without difficulties); 3:
limited with cane, tolerates prolonged orthostatism (patient goes to the supermarket,
manages to accomplish activities of daily living (ADL); 2: limited in time and distance,
with or without cane (patient who goes for a quick walk and returns, covering no more than
two blocks); 1: few meters or bedridden, uses cane or crutches (goes to the bathroom and
returns, ambulatory in the home).
Passive movements of the hip were made and measured using the universal goniometer to
evaluate mobility or range of motion (ROM). The supine position was chosen for the
measurement using Lea and Gerhardt as a reference.18 (link) Hip flexion and extension were tested with the hip at 0º
of abduction, adduction and rotation. In flexion the pelvis was stabilized to prevent
rotation and posterior tilt. Extension was measured with lower limbs in the Thomas test
position, measuring the angle between the femur and the stretcher of the extended limb.
Abduction and adduction were tested with the hip at 0º of flexion, extension and
rotation. To measure the adduction, the contralateral hip was flexed to allow the evaluation
throughout the ROM. For internal and external rotation the hip was positioned at 0º
of abduction, adduction with the knee and hip flexed at 90º.
With the purpose of establishing parameters for the evaluation criteria, the three
physiotherapist researchers received training in the instrument, carried out according to
the evaluation of the Hip Group of Santa Casa de Misericórdia de São
Paulo.
The evaluation occurred on the same day, and the patient evaluation order was determined at
random. The researchers did not communicate during the evaluation periods. Each patient was
evaluated by the three researchers, with an interval of 30 minutes between each evaluator.
Cronbach's Alpha Statistic Test was applied for the statistical analysis through version
13.0 of the SPSS (Statistical Package for Social Sciences) program. A significance level of
p≤0.05 and high reliability with α between 0.7 and 1.0 were considered.
Ugino F.K., Righetti C.M., Alves D.P., Guimarães R.P., Honda E.K, & Ono N.K. (2012). Evaluation of the reliability of the modified Merle d'Aubigné and Postel Method. Acta Ortopedica Brasileira, 20(4), 213-217.
Publication 2012
Canes Cardiovascular System Chaperone-Mediated Autophagy Crutches Ethics Committees, Research Femur Gender Hemiplegia Knee Lower Extremity Lung Pain Passive Range of Motion Patient Holding Stretchers Patients Pelvis Polyarthritis Rheumatoid Arthritis Total Hip Arthroplasty X-Rays, Diagnostic
5
Inflammatory Arthritis in TNF-ΔARE Mice
C57BL/6 TNFΔARE mice were obtained from Dr George Kollias (BSRC Fleming, Athens, Greece).6 (link) At 6–8 weeks, heterozygous TNFΔARE male mice (TNFΔARE/+, later referred as TNFΔARE) developed clinical signs of systemic polyarthritis, with 100% penetrance. The mice were housed under controlled environmental conditions (20.2 ± 2℃, 14:10 h light:dark cycle). The experiments were carried out following strict guidelines governed by the UK Animal (Scientific Procedures) Act 1986 and approved by the Birmingham Ethical Review Subcommittee. Only male animals were utilized for the examination of polyarthritis and breeding.
Naylor A.J., Desanti G., Saghir A.N, & Hardy R.S. (2017). TNFα depleting therapy improves fertility and animal welfare in TNFα-driven transgenic models of polyarthritis when administered in their routine breeding. Laboratory Animals, 52(1), 59-68.
Full text: Click here
Publication 2017
Animals Ethical Review Heterozygote Males Mice, House Mice, Inbred C57BL Polyarthritis

Most recents protocols related to «Polyarthritis»

1
Retrospective Analysis of Canine Immune-Mediated Arthritis
A retrospective review of the medical records of dogs diagnosed with non-infectious, non-erosive, idiopathic IMPA and SRMA from two referral institutions during the period between 2017 and 2021 was performed. The terms used as identifiers during the search were: “immune-mediated polyarthritis,” “steroid-responsive meningitis arteritis,” “meningitis,” “arthritis,” “polyarthritis,” “SRMA,” “IMPA.” Patients were included if they were diagnosed with non-infectious, non-erosive, idiopathic (primary) IMPA or SRMA and CRP was measured at the time of presentation. Ethical approval was granted by the Research Ethics Committee at the University of Glasgow with a reference number EA39/20.
A diagnosis was made based on consistent medical history, physical, neurological and orthopedic examination, and clinicopathologic findings (results of hematology, serum biochemical analysis for IMPA and SRMA, and thoracic and abdominal imaging for IMPA). These were coupled with the results of routine analysis of CSF collected from the cerebellomedullary or lumbar cistern. For those patients identified for the purposes of the study with SRMA, fluid analysis revealed neutrophilic or mixed neutrophilic and monocytic pleocytosis with no visible organisms, and lack of toxic neutrophils (1 (link), 2 (link)). Patients diagnosed with IMPA were identified for the purposes of the study as those whose results of synovial fluid analysis indicated neutrophilic inflammation in two or more joints.
Other diagnostic tests performed in an attempt to rule out other causes of CSF pleocytosis (imaging of the vertebral column, PCR assays to detect Toxoplasma gondii, Neospora caninum, canine distemper virus in CSF, CSF culture and serum T. gondii and N. caninum antibody titers) or secondary IMPA (echocardiography, serologic and PCR assays to detect vector-borne disease, serologic testing for Bartonella sp. infection, joint radiography, and microbial culture of blood, synovial fluid, or urine samples) were performed at the discretion of the attending clinician, taking into consideration patient demographic and historical factors, physical examination findings, preliminary test results, and client finances. Dogs were excluded if they had incomplete medical history, no definitive diagnosis or had undergone corticosteroid treatment prior to diagnosis. Additionally, dogs with SRMA were excluded if they had neurological deficits.
Data retrieved from the medical records was as follows: breed, age, body weight, gender, neutered status, month of presentation, history, physical and neurologic examination findings, CRP values at the time of diagnosis, CSF routine analysis and joint cytology results, imagining modalities performed and results, infectious disease testing, and final diagnosis.
CRP was measured quantitatively in 142 dogs (84%) and semi-quantitatively in 27 dogs (16%). For the purposes of statistical analysis semi-quantitative results were replaced as follows: 2.5 mg/L instead of <5, 150 mg/L instead of >100 mg/L, and 250 mg/L instead of >200 mg/L. The CRP serum concentration was measured using species-specific immunoturbidimetric assay for canine CRP (Gentian Canine CRP Immunoassay, Gentian AS, Moss, Norway) in one of the hospitals and using IDEXX Catalyst® CRP Test (a sandwich immunoassay, IDEXX, USA) in the other. The two assays were compared and considered to provide accurate and consistent results (26 ). The reference range for CRP was <10 mg/L.
Indzhova V., Czopowicz M., Kilpatrick S., Gutierrez-Quintana R, & Brocal J. (2023). Signalment and C-reactive protein values in dogs with immune-mediated polyarthritis and steroid responsive meningitis arteritis. Frontiers in Veterinary Science, 10, 1091318.
Full text: Click here
Publication 2023
Abdomen Adrenal Cortex Hormones Arteritis Arthritis Bartonella Infections Biological Assay Blood Culture Body Weight Canis familiaris Communicable Diseases Cytological Techniques Diagnosis Distemper Virus, Canine Echocardiography Ethics Committees, Research Gender Gentian Immunoassay Immunoglobulins Immunoturbidimetric Assay Infection Inflammation isopropyl methylphosphonic acid Joints Lumbar Region Meningitis Monocytes Mosses Neospora caninum Neutrophil Patients Physical Examination Pleocytosis Polyarthritis Serum Steroids Synovial Fluid Tests, Diagnostic Toxoplasma gondii Urine Vector Borne Diseases Vertebral Column X-Rays, Diagnostic
2
Inflammatory Diseases and Alzheimer's Risk
We designed a cohort study in which exposed participants were eligible CPRD participants who were diagnosed with one of the following inflammatory diseases: (1) RA, (2) IBD, (3) multiple sclerosis (MS), (4) psoriasis, and (5) other inflammatory polyarthropathies and systematic connective tissue disorders (OID) (eMethods, links.lww.com/WNL/C487 and eTables 1–5, links.lww.com/WNL/C486). Exposed participants were excluded if their dates of inflammatory disease diagnoses were missing or if their dates of inflammatory disease diagnoses were after or less than 1 year before their incident AD diagnosis. Each eligible exposed participant was matched on age (±5 years) and sex with 2 nonexposed participants who had no record of these inflammatory diseases from the remaining CPRD participants.
Huang J., Su B., Karhunen V., Gill D., Zuber V., Ahola-Olli A., Palaniswamy S., Auvinen J., Herzig K.H., Keinänen-Kiukaanniemi S., Salmi M., Jalkanen S., Lehtimäki T., Salomaa V., Raitakari O.T., Matthews P.M., Elliott P., Tsilidis K.K., Jarvelin M.R., Tzoulaki I, & Dehghan A. (2023). Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization. Neurology, 100(6), e568-e581.
Full text: Click here
Publication 2023
Connective Tissue Diseases Diagnosis Inflammation Multiple Sclerosis Polyarthritis Psoriasis
3
Comprehensive Psoriatic Arthritis Evaluation
Variables included in REAPSER have been previously described [8 (link)]. For this work, we considered 43 variables:

Sociodemographic data: age; sex; educational level (none, primary, secondary, university).

Family history of PsA, other types of inflammatory arthritis, and psoriasis.

Comorbidities (based on a review of medical records): age-adjusted Charlson comorbidity index [10 (link)], cardiovascular risk factors (arterial hypertension, hyperlipidemia, diabetes mellitus (insulin and non–insulin-dependent)).

Anthropometric data: body mass index (BMI).

Lifestyle: smoking, alcohol consumption [11 (link)], and physical activity (low, moderate, and high) [12 ].

The clinical situation at diagnosis of PsA: year of presentation of symptoms; clinical form (axial, peripheral, mixed); articular pattern (oligoarticular, polyarticular, distal, mutilans, spondylitis); the presence of dactylitis (yes/no).

Joint involvement and enthesitis: number of tender joints (NTJ68); the number of swollen joints (NSJ66); an extended version of the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) [13 (link)]. Polyarthritis was defined as NSJ66 ≥5.

Pain and global assessment of disease during the previous week: Global pain on a scale from 0 (no pain) to 10 (very intense); patient global assessment of disease (from 0 -feels very well- to 10 -feels very ill-); physician global assessment of disease (from 0 -minimal activity- to 10 -maximum activity-).

Cutaneous and nail involvement (evaluated by a dermatologist): cutaneous psoriasis (yes/no); year of onset of psoriasis; clinical type; specific locations; treatment of psoriasis at PsA diagnosis. Psoriasis Area and Severity Index (PASI) [14 (link)]; onychopathy (number of digits affected). Severe psoriasis was defined as PASI >10 [14 (link)].

Functional situation and quality of life: Health Assessment Questionnaire (HAQ) [15 (link)], Psoriatic Arthritis Impact of Disease (PsAID) [16 (link)].

Radiographic evaluation at baseline: Bath Ankylosing Spondylitis Radiology Index (BASRI) of the sacroiliac region [17 (link)], hand involvement according to the modified Steinbrocker method for PsA [18 (link)].

Laboratory tests: C-reactive protein (CRP), uric acid, total cholesterol, LDL cholesterol, and triglycerides. For purposes of the analysis, a series of cut-off points were established to define high values: >0.5 mg/dL for standard CRP; >0.3 mg/dL for high-sensitivity CRP; hyperuricemia if >7 mg/dL in men and >6 mg/dL in women; ≥200 mg/dL for total cholesterol; ≥100 mg/dL for LDL; ≥150 mg/dL for triglycerides.

Treatment of PsA with DMARDs: synthetic DMARDs, biologic DMARDs (the different drugs within these two groups were not considered individually).

The moderate-to-high activity of PsA (binary outcome variable) is defined as DAPSA >14 [19 (link)]. DAPSA is calculated as the sum of NTJ68, NSJ66, CRP (mg/dL), patient global assessment of disease, and global pain [19 (link)].

Rheumatologists assessing the patients did not know the objectives of this specific analysis.
Queiro R., Seoane-Mato D., Laiz A., Galindez Agirregoikoa E., Montilla C., Park H.S., Tasende J.A., Baute J.J., Joven Ibáñez B., Toniolo E., Ramírez J., Montero N., Pruenza García-Hinojosa C, & Serrano García A. (2023). Moderate-High Disease Activity in Patients with Recent-Onset Psoriatic Arthritis—Multivariable Prediction Model Based on Machine Learning. Journal of Clinical Medicine, 12(3), 931.
Full text: Click here
Publication 2023
Ankylosing Spondylitis Antirheumatic Drugs, Disease-Modifying Arthritis Bath Biopharmaceuticals Cholesterol Cholesterol, beta-Lipoprotein C Reactive Protein Dermatologist Diabetes Mellitus Diagnosis Feelings Fingers Gout High Blood Pressures Hyperlipidemia Hyperuricemia Index, Body Mass Insulin Joints Nails Pain Patients Pharmaceutical Preparations Physicians Polyarthritis Rheumatologist Skin Spondylarthritis Triglycerides Uric Acid Woman X-Rays, Diagnostic
4
Categorizing Adolescent Disease Control
To determine disease control, we gathered data and laboratory test results from the electronic medical records for the year preceding the final visit at the New Children’s Hospital. The final visit was specified as the outpatient appointment where the clinician made a formal referral to the respective adult health service. We divided participants into one of three categories according to the condition for which they were recruited: (1) good disease control and/or adherence; (2) some evidence of concern; and (3) poor disease control and/or adherence or more severe condition (see study protocol for further details).19 (link) Where appropriate, we used published cut-offs for disease control. For adolescents with diabetes, a mean glycosylated haemoglobin (the mean of all measurements across the year preceding transfer of care) ≤53 mmol/mol was categorised as good control/adherence, 54–69 mmol/mol was considered evidence of some concern, while ≥70 mmol/mol was classified as having poor control/adherence. For adolescents with rheumatic disease, the 10-joint Juvenile Arthritis Disease Activity Score was completed. For those with oligoarthritis, cut-off points of ≤0.5 (good), 0.6–2.8 (some concern) and >2.8 (poor) were used, while for those with polyarthritis, the cut-off points were ≤0.7, 0.8–4 and >4, as previously applied.19–21 (link) For adolescents with IBD, good control/adherence required minimal pain (Visual Analogue Scale, VAS 1–2), at least 80% of faecal calprotectin results <100 µg/g and always <300 µg/g, medication unchanged or reduced, and no inpatient care; indicators of some evidence of concern were VAS 3–5, <80% of faecal calprotectin results within target range or exceeded 300 µg/g even once, but no significant medication changes nor inpatient care; and for poor control/adherence any of the following: VAS ≥6, significant changes in medication, need for corticosteroids and/or commencement of biological medication or an episode of inpatient care. For rare conditions without standard criteria of disease control and/or adherence, experienced clinicians subjectively categorised participants according to their symptoms, clinical and laboratory findings, need for inpatient care and changes in medication. MK first reviewed medical records of every participant, of whom 28 (11%) were difficult to categorise. For these 28 adolescents, SK made an independent assessment of disease control. Six adolescents were categorised differently, and the final grading was based on a consensus between the two reviewers. For some analyses, we combined the three smallest subspecialties (neurology, cardiology and nephrology/organ transplant) into ‘others’.
Kallio M., Tornivuori A., Miettinen P., Kolho K.L., Culnane E., Sawyer S, & Kosola S. (2023). Disease control and psychiatric comorbidity among adolescents with chronic medical conditions: a single-centre retrospective study. BMJ Paediatrics Open, 7(1), e001605.
Publication 2023
Adolescent Adrenal Cortex Hormones Adult Arthropathy Biopharmaceuticals Cardiovascular System Diabetes Mellitus Episode of Care Feces Hemoglobin, Glycosylated Hospitalization Inpatient Juvenile Arthritis Leukocyte L1 Antigen Complex Oligoarthritis Organ Transplantation Outpatients Pain Pharmaceutical Preparations Polyarthritis Rare Diseases Rheumatism Visual Analog Pain Scale
5
Retrospective Study of COVID-19-Induced Reactive Arthritis

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Antibodies Antibodies, Antinuclear Arthritis Arthritis, Psoriatic Arthritis, Reactive Cell-Derived Microparticles Chemiluminescent Assays COVID-19 Antibody Testing COVID 19 cyclic citrullinated peptide Degenerative Arthritides Gout Immunoassay Immunoglobulin G Immunoglobulins Inflammation Joints Lupus Erythematosus, Systemic Mental Recall Oligonucleotides Outpatients Patients Physicians Polyarthritis Polymerase Chain Reaction Relapse Rheumatoid Arthritis Rheumatoid Factor Spondylarthropathies Synovitis Ultrasonics

Top products related to «Polyarthritis»

1
Jmp 15 by SAS Institute
Sourced in United States, Japan, Germany
JMP 15 is a statistical discovery software that enables users to explore, visualize, and analyze data. It provides a range of analytical tools and capabilities for data manipulation, modeling, and reporting.
2
Isoflo by Abbott
Sourced in United States, United Kingdom, Spain, Israel, Belgium, Australia
IsoFlo is a laboratory equipment product offered by Abbott. It is designed for use in clinical and research settings. IsoFlo serves as a tool for analysis and measurement, but a detailed description of its core function cannot be provided while maintaining an unbiased and factual approach.
3
Mycobacterium butyricum by BD
Sourced in United States
Mycobacterium butyricum is a bacterial strain used in laboratory settings. It is a Gram-positive, acid-fast bacillus known for its ability to produce butyric acid. This strain may be utilized in various microbiology research applications.
4
Complete freund adjuvant (cfa) by Chondrex
Sourced in United States
The CFA is a laboratory equipment designed for the measurement of collagen-induced arthritis. It is used for the assessment of arthritis in experimental animal models.
5
M tuberculosis by Merck Group
Sourced in United States
The M. tuberculosis lab equipment is used for the detection and identification of the Mycobacterium tuberculosis bacterium, the causative agent of tuberculosis. The equipment provides a standardized and reliable method for the analysis of clinical samples, allowing for accurate diagnosis and disease monitoring.
6
Tryptone soya broth (tsb) by Thermo Fisher Scientific
Sourced in United Kingdom, United States, Italy, Germany, Australia
Tryptone Soya Broth (TSB) is a general-purpose culture medium used for the growth and cultivation of a wide range of microorganisms, including bacteria, yeasts, and fungi. It provides a nutritious environment that supports the growth and proliferation of these microorganisms.
7
Wistar han rats by Charles River Laboratories
Sourced in Germany, France, United States, United Kingdom
Wistar Han rats are a widely used rodent model in biomedical research. They are a substrain of the Wistar rat, known for their robust health, reproductive performance, and genetic stability.
8
Sprague dawley ofa rats by Charles River Laboratories
Sourced in France
The Sprague-Dawley OFA rats are a widely used outbred albino rat strain. They are a general-purpose rat model commonly used in research and testing across various fields.
9
Spss statistics version 25 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Poland, Australia, Austria
SPSS Statistics version 25 is a software package used for interactive or batched statistical data analysis. It provides a comprehensive set of tools for data access, data management, and data analysis, as well as tools for model building and deployment.
10
Tryptone soya agar tsa by Thermo Fisher Scientific
Sourced in United Kingdom, Spain, United States
Tryptone Soya Agar (TSA) is a general-purpose growth medium used for the cultivation of a wide range of microorganisms, including bacteria and fungi. It provides the necessary nutrients and growth factors to support the proliferation of these microorganisms in a laboratory setting.

More about "Polyarthritis"

Polyarthritis, also known as multifocal arthritis or inflammatory polyarthritis, is a condition characterized by inflammation and swelling in multiple joints.
It can be caused by a variety of underlying conditions, such as rheumatoid arthritis, psoriatic arthritis, or reactive arthritis.
Symptoms may include joint pain, stiffness, and reduced range of motion.
Accurate diagnosis and effective treatment are crucial for managing polyarthritis and preventing long-term complications.
Researchers often utilize animal models, such as Wistar Han rats and Sprague-Dawley OFA rats, to study the pathogenesis and evaluate potential therapies for polyarthritis.
Induction of polyarthritis in these models may involve the use of substances like Mycobacterium butyricum, CFA (Complete Freund's Adjuvant), or M. tuberculosis.
Statistical analysis of polyarthritis research data is often conducted using software like SPSS Statistics version 25.
Researchers may also leverage growth media like Tryptone Soya Broth (TSB) and Tryptone Soya Agar (TSA) for culturing and maintaining cell lines or bacterial strains relevant to their studies.
Optimizing research protocols for the identification and evaluation of polyarthritis is essential for advancing our understanding of this condition and improving patient outcomes.
PubCompare.ai's AI-driven platform can help researchers effortlessly locate and compare protocols from literature, pre-prints, and patents, ensuring reproducible and accurate results.
By leveraging the power of AI, researchers can identify the best protocols and products for their polyarthritis research, ultimately accelerating the development of effective treatments and enhancing the quality of life for individuals affected by this condition.